Almirall starts the year with solid growth

The first quarter was a good one for Almirall, and the new CEO hopes to live up to the 2021 guidance with the help of two potential EU approvals.

Photo: Almirall / PR

During the first three months of the year, Almirall has generated EUR 215m in sales, although only a small portion of this was in the dermatology business, where Almirall competes with Leo Pharma.

Here, sales grew from EUR 86m to just under EUR 89m.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs